Thalidomide
NICE won’t back Revlimid in new setting
July 31, 2014Medical Communications, Sales and Marketing Celgene, NICE, Revlimid, Thalidomide, multiple myeloma
NICE has once again said it does not think that Celgene’s rare cancer drug Revlimid should be used on the …
Celgene ‘downplayed’ Thalomid, Revlimid risks
February 7, 2014Medical Communications, Sales and Marketing Celgene, Revlimid, Thalidomide, thalomid
A former sales representative for US pharma firm Celgene is accusing her old company of promoting two of its key …
NICE recommends thalidomide ahead of Velcade
July 27, 2011Sales and Marketing NICE, Thalidomide, Velcade
NICE has recommended Celgene’s thalidomide ahead of J&J’s Velcade for multiple myeloma. Celgene’s drug is recommended in combination with an …
NICE backs Celgene’s thalidomide and Janssen’s Velcade
June 21, 2011Sales and Marketing NICE, Thalidomide, Velcade, multiple myeloma
Celgene’s thalidomide and Janssen-Cilag’s Velcade have been given the thumbs up by NICE as a treatment for a cancer that …
Janssen to appeal against Velcade decision
August 26, 2010Medical Communications, Sales and Marketing NICE, Thalidomide, Velcade, multiple myeloma
Celgene’s Thalidomide has been recommended by NICE for multiple myeloma ahead of Janssen-Cilag’s Velcade. A final appraisal determination says that …
Celgene
January 1, 2010Research and Development, Sales and Marketing Abraxane, Celgene, Revlimid, Thalidomide
Founded in 1986, Celgene was created as a spin off from the Celanese Corporation. Two years later, the company received …
